Monitoring Desk
ISLAMABAD/WASHINGTON: Moderna Inc would make specific contingent development, commercial, and regulatory milestone payments to the United States (US) National Institutes of Health (NIH) related to the development of covid vaccines, the company said in a filing.
Moderna and US agency
Moderna and the NIH had entered into a licence agreement in December 2022 related to certain patents concerning the Covid-19 vaccine products, the filing showed, according to Reuters.
The vaccine maker first disclosed a deal in its fourth-quarter earnings release stating it was missed profit estimates hurt by a royalty payment to the NIH.
Moderna said that the agreement would pay low single-digit royalties on future net sales and minimum annual royalties.
